Crinetics’ first sales numbers are off to a strong start.
The newly-commercial biotech said sales for its rare disease drug Palsonify surpassed $5 million in the final three months of 2025, the first full quarter …
Read More from Endpoints News
Crinetics reports robust full-quarter sales for rare disease drug Palsonify
